Citius Oncology, Inc. (CTOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($35.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Citius Oncology, Inc. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Citius Oncology, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Citius Oncology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Oncology, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Midsummer AB (publ)
ST:MIDS
|
-0.108x |
|
Drb Industrial
KO:163560
|
0.027x |
|
Facephi Biometria SA
MC:FACE
|
0.027x |
|
Softtech Engineers Limited
NSE:SOFTTECH
|
0.042x |
|
Nordic Resources Ltd
AU:NNL
|
-0.018x |
|
Commercial Vehicle Group Inc
NASDAQ:CVGI
|
-0.012x |
|
Spruce Ridge Resources Ltd.
V:SHL
|
-0.048x |
|
Choong Ang Vaccine Laboratory Co. Ltd
KQ:072020
|
0.022x |
Annual Cash Flow Conversion Efficiency for Citius Oncology, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Citius Oncology, Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $44.87 Million | $-5.49 Million | -0.122x | -4570.02% |
| 2024-09-30 | $46.14 Million | $126.35K | 0.003x | +111.63% |
| 2023-09-30 | $25.54 Million | $-601.30K | -0.024x | -1680.38% |
| 2022-09-30 | $36.27 Million | $-47.97K | -0.001x | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more